# Nicotine nasal spray for smoking cessation in primary care

Submission date	Recruitment status	Prospectively registered		
12/03/2010	No longer recruiting	☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
15/04/2010	Completed	[X] Results		
Last Edited	Condition category	Individual participant data		
08/08/2011	Mental and Behavioural Disorders			

## Plain English summary of protocol

Not provided at time of registration

## Contact information

## Type(s)

Scientific

#### Contact name

Mr John Stapleton

#### Contact details

Institute Of Psychiatry Kings College London Postal Box P075 4 Windsor Walk London United Kingdom SE5 8AF j.stapleton@iop.kcl.ac.uk

## Additional identifiers

## Protocol serial number

9820384; G7804283

## Study information

#### Scientific Title

Randomised placebo controlled trial of nicotine nasal spray for smoking cessation in primary care

#### Acronym

**GPNNS** 

## **Study objectives**

To compare the effectiveness of nicotine nasal spray and placebo when given with brief GP and nurse support in primary care.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

King's Lynn Medical Research Ethics Committee approved on the 21st November 1995 (ref: 95-NNNS-014 (34/95))

## Study design

Multicentre randomised placebo controlled trial

## Primary study design

Interventional

## Study type(s)

Treatment

## Health condition(s) or problem(s) studied

Tobacco dependence

#### **Interventions**

Active or placebo nicotine nasal spray for 12 weeks plus brief primary care counseling support. Total duration of follow-up is 12 weeks.

## Intervention Type

Other

#### Phase

Not Applicable

## Primary outcome(s)

Co-verified complete abstinence from smoking for weeks 3 to 12.

## Key secondary outcome(s))

- 1. Co-verified complete abstinence from smoking during 12 weeks
- 2. Adverse events

## Completion date

01/02/1999

## Eligibility

## Key inclusion criteria

- 1. Smokers: smoking for at least 3 years
- 2. Aged 20 60 years, either sex
- 3. Smokes 15 or more cigarettes a day
- 4. Motivated to stop

## Participant type(s)

**Patient** 

## Healthy volunteers allowed

No

## Age group

Adult

#### Sex

All

## Key exclusion criteria

- 1. Myocardial infarction within 3 years
- 2. Chronic nasal disorder
- 3. Pregnancy, intending pregnancy
- 4. Breast feeding
- 5. Current psychiatric care
- 6. Current use of psychotropic drugs

## Date of first enrolment

01/02/1996

#### Date of final enrolment

01/02/1999

## Locations

#### Countries of recruitment

**United Kingdom** 

England

## Study participating centre Institute Of Psychiatry

London United Kingdom SE5 8AF

## Sponsor information

## Organisation

McNeil AB (Sweden) - formally Pharmacia and Upjohn

#### **ROR**

https://ror.org/020jwmq86

## Funder(s)

## Funder type

Research council

#### Funder Name

Kings College London (UK) - Institute of Psychiatry, staff supported by MRC Programme Grant (ref: G7804283)

#### Funder Name

McNeil AB (Sweden) - formally Pharmacia and Upjohn, supported trial costs

## **Results and Publications**

Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## **Study outputs**

Output type	Details	Date created Date added	Peer reviewed?	Patient-facing?
Results article	results	01/04/2011	Yes	No
Participant information sheet	Participant information sheet	11/11/2025 11/11/2025	No	Yes